Dwivedi, M., Tiwari, S., Kemp, E.H. orcid.org/0000-0002-0313-8916 et al. (1 more author) (2022) Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics. Heliyon, 8 (8). e10450. ISSN 2405-8440
Abstract
Regulatory T cells (Tregs) play an essential role in maintaining immune tolerance and suppressing inflammation. However, Tregs present major hurdle in eliciting potent anti-cancer immune responses. Therefore, curbing the activity of Tregs represents a novel and efficient way towards successful immunotherapy of cancer. Moreover, there is an emerging interest in harnessing Treg-based strategies for augmenting anti-cancer immunity in different types of the disease. This review summarises the crucial mechanisms of Tregs’ mediated suppression of anti-cancer immunity and strategies to suppress or to alter such Tregs to improve the immune response against tumors. Highlighting important clinical studies, the review also describes current Treg-based therapeutic interventions in cancer, and discusses Treg-suppression by molecular targeting, which may emerge as an effective cancer immunotherapy and as an alternative to detrimental chemotherapeutic agents.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/). |
Keywords: | Anti-cancer immunity; Cancer; CD8+ T cells; CD4+ T cells; Regulatory T cells; Tumor-infiltrating lymphocytes |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 09 Sep 2022 10:35 |
Last Modified: | 09 Sep 2022 10:35 |
Status: | Published |
Publisher: | Elsevier BV |
Refereed: | Yes |
Identification Number: | 10.1016/j.heliyon.2022.e10450 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:190563 |